ERBB2 and breast carcinoma: HER2-enriched breast cancer has been reported to be associated with aggressive clinical features and a poor prognosis, nevertheless, due to the development of anti-HER2 agents the outcomes of HER2-enriched breast cancer patients were significantly improved (2–5).